Science and research

Resistance of Chronic Myeloid Leukemia (CML) to Treatment with Tyrosine Kinase Inhibitors

Despite the high efficiency of tyrosine kinase inhibitors (TKIs) in CML treatment, about 20-30% of patients do not respond to TKI therapy or develop resistance. While mutations in the kinase domain of BCR-ABL protein are on the basis of the treatment failure in about 50 % of those cases, a variety of other mechanisms have been identified and others remain uncovered.

Using different proteomic approaches, we search for early molecular markers and unknown mechanisms of resistance development as well as for possible alternative targets to eliminate the resistant cells.

Quick contact

Head of Science and Research Division
Tel:+420 221 977 208

Deputy head of Science and Research Division
Tel:+420 221 977 269
Tel:+420 221 977 364

Tel:+420 221 977 247

Opening hours

Mo – Fr: 7:00–18:00
Weekends: 9:00–13:00

Mo – Fr: 7:00–10:30

Inpatient department
Mo – Fr: 13:00–18:00

ICU and Transplant unit
Mo – Fr: 14:00–17:00

How to find us


Ústav hematologie a krevní transfuze
(​Institute of Hematology and Blood Transfusion)

U Nemocnice 2094/1
128 00 Praha 2

The nearest underground station: Karlovo náměstí (line B)

The nearest tram station: Karlovo náměstí (10, 16, 22), Moráň (3, 6, 10, 16, 18, 24)

The nearest bus station: U Nemocnice (148), Karlovo náměstí (176)

How to get here